Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 18;14(4):e1002276.
doi: 10.1371/journal.pmed.1002276. eCollection 2017 Apr.

An open source pharma roadmap

Manica Balasegaram  1 , Peter Kolb  2 , John McKew  3 , Jaykumar Menon  4 , Piero Olliaro  5   6 , Tomasz Sablinski  7 , Zakir Thomas  8 , Matthew H Todd  9 , Els Torreele  10 , John Wilbanks  11
Affiliations

An open source pharma roadmap

Manica Balasegaram et al. PLoS Med. .

Abstract

In an Essay, Matthew Todd and colleagues discuss an open source approach to drug development.

PubMed Disclaimer

Conflict of interest statement

TS is CEO and founder of Transparency Life Sciences and an employee of Auven Therapeutics, as well as owning equity in biotech companies. JM and MHT were members of a group that received a grant from Tata Trusts (India) in 2015 to establish the Open Source Pharma Foundation, a not-for-profit agency working in India to support open source drug discovery initiatives worldwide, in part by advocating the potential public health benefits of such initiatives. The Foundation was formally created in 2016 but has not at the time of writing begun operations. ZT was Project Director of the Open Source Drug Discovery Project, CSIR, India. MHT is founder of the Open Source Malaria Consortium. These are non-profit, government-led initiatives pursuing open models of drug discovery and development.

References

    1. Scannell JW, Blanckley A, Boldon H, Warrington B (2012) Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 11: 191–200. 10.1038/nrd3681 - DOI - PubMed
    1. Moon S, Bermudez J, 't Hoen E (2012) Innovation and access to medicines for neglected populations: could a treaty address a broken pharmaceutical R&D system? PLoS Med 9(5): e1001218 10.1371/journal.pmed.1001218 - DOI - PMC - PubMed
    1. Dentico N, Ford N (2005) The courage to change the rules: a proposal for an essential health R&D treaty. PLoS Med 2(2): e14 10.1371/journal.pmed.0020014 - DOI - PMC - PubMed
    1. Incentivising research and development for the diseases of poverty (2005) Working paper of the WHO Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH). http://www.who.int/intellectualproperty/submissions/IncentivisingRD.pdf. Accessed Feb 16th 2017.
    1. Goldman M, Compton C, Mittleman BB (2013) Public-private partnerships as driving forces in the quest for innovative medicines. Clin Transl Med 2:2 10.1186/2001-1326-2-2 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances